Which drug class does Entresto belong to?

Which drug class does Entresto belong to?

• A. ACE inhibitors
• B. Aldosterone inhibitors
• C. Combined angiotensin receptor neprilysin inhibitors
• D. Beta blockers

Answer: (C)

Entresto is classified as a combined angiotensin receptor neprilysin inhibitor. This drug works by combining the effects of an angiotensin receptor blocker (ARB) and the inhibition of neprilysin, an enzyme that degrades several peptides including natriuretic peptides which play a role in cardiovascular homeostasis. The dual mechanism helps to reduce blood pressure, decrease the strain on the heart, and improve outcomes for patients with heart failure. By inhibiting neprilysin, Entresto increases the levels of beneficial peptides that improve kidney function, promote vasodilation, and reduce cardiovascular and renal morbidity and mortality. This combination is particularly effective compared to using either drug alone, hence it is uniquely positioned in the treatment of heart failure, making it distinct from the other classes mentioned in the options. Other options, such as ACE inhibitors, aldosterone inhibitors, and beta-blockers, serve different functions and mechanisms in managing cardiovascular conditions but do not encompass the unique dual action that Entresto provides. This specificity in its design is a significant factor in its efficacy for heart failure management.

Entresto is classified as a combined angiotensin receptor neprilysin inhibitor. This drug works by combining the effects of an angiotensin receptor blocker (ARB) and the inhibition of neprilysin, an enzyme that degrades several peptides including natriuretic peptides which play a role in cardiovascular homeostasis. The dual mechanism helps to reduce blood pressure, decrease the strain on the heart, and improve outcomes for patients with heart failure.

By inhibiting neprilysin, Entresto increases the levels of beneficial peptides that improve kidney function, promote vasodilation, and reduce cardiovascular and renal morbidity and mortality. This combination is particularly effective compared to using either drug alone, hence it is uniquely positioned in the treatment of heart failure, making it distinct from the other classes mentioned in the options.

Other options, such as ACE inhibitors, aldosterone inhibitors, and beta-blockers, serve different functions and mechanisms in managing cardiovascular conditions but do not encompass the unique dual action that Entresto provides. This specificity in its design is a significant factor in its efficacy for heart failure management.